Therapy of P388 leukemia with benzaldehyde.
Optimal schedules of benzaldehyde (50-100 mg kg-1 intraperitoneally) on day 1 or on several days after inoculation of 10(5) P388 leukemia cells to DBA 2J mice increased survival by 70-100%. No significant prolongation of survival was observed between the various schedules of benzaldehyde treatment. Significantly longer survival was observed on day 30 after benzaldehyde treatment with 100 mg kg-1 on day 1 or 50 mg kg-1 on days 1-4 as compared to untreated controls, but no cure was achieved with any schedule and dose of benzaldehyde. No or minimal activity of benzaldehyde on L1210 and L5178Y leukemias, Ehrlich adenocarcinoma and Yoshida sarcoma was observed.
Balázová
E
E
Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Czechoslovakia.
Koza
I
I
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001547:Benzaldehydes / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D007941:Leukemia P388 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA
D000970:Antineoplastic Agents; D001547:Benzaldehydes; C032175:benzaldehyde; D005472:Fluorouracil